Biomarkers of PARP Inhibitor Response in Ovarian Cancer

Gene copy number profile of extracellular vesicles in body fluid to determine the sensitivity of ovarian cancer to the anticancer drug PARP inhibitors.


  • Liquid biopsy can accurately predict response to PARP inhibitor therapy in patients with ovarian cancer.

Background and Technology

Recently, PARP (poly ADP-ribose polymerase) inhibitors have been approved as molecular target drugs for ovarian cancer maintenance therapy. Conventional molecular target drugs include VEGFR inhibitors, but there are no clear drug selection criteria at this time. MyChoice has been used as a test to determine response to PARP inhibitor therapy in ovarian cancer patients, but it is not sufficient. MyChoice is a method to determine PARP inhibitor responder based on HRD Score from genetic HRD error analysis in BRCA1/2 gene mutations in breast cancer patients.
PARP inhibitors are effective in hereditary ovarian cancer, but responder diagnosis is necessary in sporadic cases. Recently, it has been reported that copy number of cancer-related genes is a problem in ovarian cancer. We treated ovarian cancer maintenance therapy patients with PARP inhibitors for about 3 years and analyzed the copy number of cancer-related genes in tissue and fluid exosomes using droplet digital PCR for each responder and non-responder group. As a result, we found that the copy number of specific genes can determine the sensitivity to PARP inhibitors.
We are also studying various other markers and candidate drugs for gynecological diseases, as well as extracellular vesicles.

Reference and Patent

  • Patent pending

Principal Investigator

Akira YOKOI (Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tokai National Higher Education and Research System)

Current Stage and Next Step

  • Currently, we have identified multiple gene copy number markers that predict response to PARP inhibitor therapy for ovarian cancer patients.
  • In the future, we plan to further increase the number of cases analyzed to improve the reliability of marker refinement and determination.
  • We are looking for pharmaceutical companies to develop PARP inhibitors, droplet digital PCR device companies, and diagnostic service companies as collaborative partners.


Project No: BK-04309


Other than Medicine


Inquiry Form

    Your name (*required)

    E-mail address (*required)

    Company name

    Message (*required)

    Following submission of your inquiry

    We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


    Our support is provided free of charge.
    The information submitted on this form is for business development use only.

    By clicking "Send", you are agreeing to our Privacy Policy.
    If you have questions please reach out to info (at)

    About Tech Manage Corp.
    Copyright © Tech Manage Corp. All Rights Reserved.
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.